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Background: Newborns exhibit distinct immune responses and are at high risk of
infection. Neonatal immunization with BCG, the live attenuated vaccine against tuberculosis
(TB), is associated with broad protection against a range of unrelated pathogens, possibly
reflecting vaccine-induced training of innate immune cells (“innate memory”). However, little is
known regarding the impact of age on BCG-induced innate responses.
Objective: Establish an age-specific human monocyte in vitro training platform to
characterize and compare BCG-induced primary and memory cytokine responses and
immunometabolic shifts.
Design/Methods: Human neonatal and adult CD33-selected monocytes were
stimulated for 24h with RPMI (control) or BCG (Danish strain) in 10% autologous
serum, washed and cultured for 5 additional days, prior to re-stimulation with the TLR4
agonist LPS for another 24h. Supernatants were collected at Day 1 (D1) to measure
primary innate responses and at Day 7 (D7) to assessmemory innate responses by ELISA
and multiplex cytokine and chemokine assays. Lactate, a signature metabolite increased
during trained immunity, was measured by colorimetric assay.
Results: Cytokine production by human monocytes differed significantly by age at D1
(primary, BCG 1:750 and 1:100 vol/vol, p<0.0001) and D7 (innate memory response, BCG
1:100 vol/vol, p<0.05). Compared to RPMI control, newborn monocytes demonstrated
greater TNF (1:100, 1:10 vol/vol, p<0.01) and IL-12p40 (1:100 vol/vol, p<0.05) production
than adult monocytes (1:100, p<0.05). At D7, while BCG-trained adult monocytes, as
previously reported, demonstrated enhanced LPS-induced TNF production, BCG-trained
newborn monocytes demonstrated tolerization, as evidenced by significantly diminished
Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 6743341
Edited by:
Federico Martinon-Torres,













†These authors have contributed
equally to this work and share
senior authorship
Specialty section:
This article was submitted to
Vaccines and
Molecular Therapeutics,
a section of the journal
Frontiers in Immunology
Received: 01 March 2021
Accepted: 02 June 2021
Published: 13 July 2021
Citation:
Angelidou A, Diray-Arce J,
Conti MG, Netea M-G, Blok BA, Liu M,
Sanchez-Schmitz G, Ozonoff A, van
Haren SD and Levy O (2021) Human
Newborn Monocytes Demonstrate
Distinct BCG-Induced Primary and
Trained Innate Cytokine Production




published: 13 July 2021
doi: 10.3389/fimmu.2021.674334
subsequent LPS-induced TNF (RPMI vs. BCG 1:10, p <0.01), IL-10 and CCL5 production
(p<0.05). With the exception of IL-1RA production by newborn monocytes, BCG-induced
monocyte production of D1 cytokines/chemokines was inversely correlated with D7 LPS-
induced TNF in both age groups (p<0.0001). Compared to BCG-trained adult monocytes,
newborn monocytes demonstrated markedly impaired BCG-induced production of lactate,
a metabolite implicated in immune training in adults.
Conclusions: BCG-induced human monocyte primary- and memory-innate cytokine
responses were age-dependent and accompanied by distinct immunometabolic shifts
that impact both glycolysis and training. Our results suggest that immune ontogeny may
shape innate responses to live attenuated vaccines, suggesting age-specific approaches
to leverage innate training for broad protection against infection.
Keywords: Bacille Calmette-Guérin (BCG) vaccine, cord blood, cytokines, lactate, newborn monocytes,
immunometabolism, trained immunity
INTRODUCTION
As compared to other age groups, human newborns are highly
susceptible to infections due in part to functionally distinct
innate (1) and adaptive immunity (2). Epidemiologic studies
have linked early life BCG immunization to an unanticipated
reduction (~50%) in all-cause mortality, greatly exceeding that
attributable to tuberculosis (TB) (3, 4). These observations
suggest BCG induces heterologous protection against
antigenically diverse, unrelated pathogens. One of the
suggested mechanisms for heterologous protection against
infection in the context of BCG vaccination is the novel
concept of innate immune memory, also termed as “trained
immunity” (5). Trained immunity is the ability of innate
immune cells to mount an altered response against infection
following a previous unrelated infection or vaccination.
Several lines of evidence suggest that trained immunity occurs in
newborns (6). In mice, pre-treatment with Toll-like receptor (TLR)
agonists enhances subsequent responses to polymicrobial sepsis (7)
and treatment with BCG results in enhanced emergency
granulopoiesis (8). Evidence that such trained immunity occurs in
human newborns includes: (a) critically ill preterm newborns
demonstrate enhanced pathogen-specific mononuclear cell pattern
recognition receptor (PRR) expression in the setting of Gram-
positive or Gram-negative bacteremia (9); and (b) histologic
chorioamnionitis affecting preterm infants is associated with a
significantly reduced risk of late onset bacterial sepsis (10). These
observations suggest the existence of neonatal innate memory that
alters responses to subsequent unrelated microbial challenges (11).
Early life immunization in Guinea-Bissau with BCG had
beneficial effects on overall mortality, especially when provided
at birth, with the largest effect seen in low birth weight newborns
and during the first 2 months of life (12–14). In addition to
reduced mortality, heterologous beneficial BCG effects in early life
include reductions in respiratory infections and sepsis, in both
high- and low-income settings (15, 16). In vitro, stimulation of
BCG-trained adult peripheral blood mononuclear cells (PBMCs)
with heterologous TLR agonists and bacteria led to increased
production of TNF (17). BCG, given 1 month prior to an
infectious challenge, enhanced clearance of yellow fever vaccine
strain viremia, an effect that correlated with higher pro-
inflammatory cytokine production (TNF, IL-1b, IL-6) from
BCG-vaccinated adult volunteers, with a crucial role for IL-1b
production (18). Such trained immunity effects have been ascribed
to genome-wide epigenetic reprogramming of monocytes (Mos),
which in adults is accompanied by metabolic rewiring, crucial for
the induction of the histone modifications and functional changes
underlying BCG-induced trained immunity in adults (19).
Ongoing clinical trials are underway to assess BCG pathogen-
agnostic protection against COVID-19 (20).
The extent, mechanism and ontogeny of trained immunity in
early life remain incompletely defined. Understanding how
BCG-induced innate immune engagement, including the
enhancement of Th-polarizing cytokine production by antigen-
presenting cells, varies by age, is of basic and translational
importance (21, 22). In this study, we compared the impact of
BCG stimulation on innate cytokine and chemokine responses
by CD33+ monocytes characterizing both primary and memory
innate responses of human newborn and adult monocytes to a
subsequent stimulation with lipopolysaccharide (LPS). We
found that in marked contrast to increased cytokine induction
by BCG-trained adult monocytes, BCG-trained newborn
monocytes mounted a tolerogenic response to endotoxin.
Remarkably BCG-induced cytokines and chemokines at Day 1
inversely correlated with subsequent LPS-induced TNF
production on Day 7. Moreover, human newborn monocytes
failed to produce lactate in response to BCG, suggesting distinct
immunometabolism in early life that could contribute to age-
dependent effects of BCG.
METHODS
Human Blood Collection
In accordance with approved protocols from the Institutional
Review Board (IRB) of the Beth Israel Deaconess Medical Center,
Angelidou et al. BCG Trained Immunity in Newborns
Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 6743342
Boston, MA (protocol number 2011P-000118) and The Brigham
& Women’s Hospital, Boston, MA (protocol number 2000-P-
000117), human cord blood samples were collected from healthy
full-term cesarean deliveries (>37 weeks gestational age). All de-
identified blood samples from adult (age 18–40 years old)
participants were collected with approval from the IRB of
Boston Children’s Hospital, Boston, MA (protocol number
307-05-0223), after written informed consent. Small blood
samples (10-15ml) were collected in vacutainer serum
collection tubes (BD Biosciences; San Jose, CA) to secure
autologous serum from each participant, and the remaining
blood volume was anti-coagulated with 15 U/ml of pyrogen-
free heparin sodium (Sagent Pharmaceuticals; Schaumburg, IL,
USA) and assayed within 4h. Prior to study blood collection,
none of the study participants had ever received BCG.
Autologous Serum Preparation
Blood collected in vacutainer serum collection tubes was left
undisturbed at room temperature for 30 min and allowed to clot,
then centrifuged at 1500 × g for 10 minutes. Serum was
maintained at 2-8°C during handling or apportioned in 0.5-1
ml aliquots and stored in -20°C until use.
Isolation of Human Mononuclear Cells and
Monocytes
Heparinized cord blood from newborns and peripheral blood
from adults was centrifuged for 10 min at 500 × g, then the upper
layer of clear yellow plasma was removed. The remaining blood
was reconstituted to its original volume by resuspending in
Dulbecco ’s Phosphate Buffered Sal ine (DPBS, Li fe
Technologies, Carlsbad, CA). Then, 25 ml of reconstituted
blood was layered on to 15 ml of Ficoll-Hypaque gradients
(Ficoll-Paque PREMIUM; GE Healthcare, Waukesha, WI) and
centrifuged for 30 min at 500 × g. After Ficoll separation, the
mononuclear cell fraction was collected. Monocytes were then
isolated from mononuclear cell fractions by positive selection
with magnetic CD33 MicroBeads, performed according to the
manufacturer’s instructions (Miltenyi Biotec, Auburn, CA).
CD33 vs. CD14 was chosen in order to avoid induction of
non-physiological activation and provide more natural
monocyte heterogeneity (23, 24). Purity was checked by flow
cytometry and was always > 90%.
Trained Immunity Assay
Following isolation,monocyteswere countedand re-suspended ina
Roswell Park Memorial Institute (RPMI) 1640 medium
supplemented with L-glutamine, penicillin, streptomycin and
10% autologous serum at a concentration of 1 million monocytes/
ml. After a 1h resting phase, monocytes were stimulated with BCG
or RPMI (negative control) in duplicate: one singlicate was used to
study primary innate responses and supernatants were filtered and
harvested after 24h for cytokine measurements and lactate
measurements. The other singlicate was used to study trained
immunity: After 24h, BCG was washed out with a calcium- and
magnesium-free PBS [PBS(−)], medium was replenished, and
BCG-trained or control monocytes were incubated at 37°C for 5
dayswith an interimmedium replenishing step onDay 3 of culture.
On Day 6, supernatants were collected and a second stimulus,
lipopolysaccharide from Salmonella minnesota (LPS-SM
Ultrapure, Invivogen; San Diego, CA) was added. After 24 h
incubation, supernatants were harvested on Day 7 of culture for
cytokine and lactate measurements (Figure 1).
Cytokine/Chemokine Assays
Supernatants from the trained immunity assay were analyzed for
TNF with a human ELISA kit (BD Opteia ELISA set, BD
Biosciences; San Jose, CA) as per the manufacturer’s directions.
ELISA plates were read on a Versamax microplate reader with
SoftMax Pro Version 5 (both from Molecular Devices;
Sunnyville, CA). A fluorescent bead-based multianalyte xMAP
technology cytokine kit (Milliplex Human Cytokine/Chemokine
Immunoassay, Millipore Corp; Billerica, MA) was employed to
measure the concentration of 41 analytes including Th1-, Th2-,
and Th17- cytokines, chemokines and hematopoietic factors.
Assays employed a Luminex 200 Bioanalyzer (Luminex Corp; TX,
USA) set to acquire at least 50 events per cytokine. Multiplex
cytokine/chemokine data were analyzed using BeadViewmultiplex
Data Analysis Software (v.1), according to the manufacturer’s
instructions (Millipore).
Lactate Measurements
Lactate concentrations in culture supernatants were measured
post-primary stimulation (Day 1) and post-secondary
stimulation (Day 7) using a colorimetric assay (Lactate Kit II,
Biovision; Milpitas, CA).
Statistical Analysis
Cytokine/chemokine concentrations were normalized to RPMI
control, log2-transformed and represent log-fold-change over
RPMI. To assess statistical significance, differences between
individual treatment conditions (for example BCG 1:10 vs
RPMI) were evaluated by Student’s t-test, while differences
between age groups and across BCG concentrations were
evaluated by ANOVA.
Lactate production was normalized to the vehicle condition
on Day 1 and log2-transformed. The paired Student’s t-test was
used for comparison of trained vs. untrained conditions and
within each age group over time. Unpaired Student’s t-test was
used for comparison of similar conditions between age groups.
We used Pearson correlation to evaluate associations between
primary cytokine/chemokine concentrations (Day 1) and
subsequent LPS-induced TNF trained immune responses
(Day 7). A p-value <0.05 was considered statistically significant.
Statistical and graphical analysis was performed using Prism 7
software (Graph Pad Software Inc; La Jolla, CA), R version 4.0 and
geepack v 1.3-2 package.
RESULTS
A human neonatal in vitro trained immunity platform was
designed based on studies of adult monocyte BCG-induced
trained immunity in vitro assays, which were used as a
benchmark (25). In accordance with these studies, we employed
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LPS, a TLR4 agonist which is not present on the mycobacterial
surface, as our heterologous stimulus of choice. We defined Day 0
as the day of blood collection and primary monocyte stimulation.
We confirmed that assessment of a trained immunity response
was optimal after 7 days of culture and used this as our timepoint
of choice.
Primary BCG-induced TNF production by human CD33+ Mos
isolated from adult peripheral and cord blood mononuclear cells
was assessed after in vitro stimulation. Newborn Mos stimulated
with increasing concentrations (vol/vol 1:750, 1:100, 1:10) of BCG-
Denmark generated concentration-dependent increases in TNF
production compared to control RPMI medium (RM 1-way
ANOVA, ***p=0.0002; Figure 2). Although adult Mos also
exhibited concentration-dependent increases in TNF production
compared to control RPMI medium (RM 1-way ANOVA,
*p=0.01), they produced significantly lower BCG-induced TNF
compared to newborn Mos for each BCG concentration and
overall (2-way ANOVA, *p=0.01) (Figure 2). Absolute TNF
concentrations are shown in Supplementary Figure 1. Additional
analyses fitting a linear trend showed that TNF values increase 80%
on average for each step up in concentration among newborns
(p<0.0001) vs. 56% increase for each step up in concentration
among adults (interaction p=0.02). Overall, adult Mos produce 56%
lower TNF on average compared to newborn Mos (p=0.002).
The effect of BCG on production of a range of cytokines and
chemokines was further examined in human Mos stimulated
with a low or high BCG concentration- 1:750 (vol/vol) and 1:100
(vol/vol), respectively (Supplementary Table 1). Primary (24h
after BCG stimulation) BCG-induced Mo cytokine/chemokine
production significantly differed by age (RM-ANOVA, BCG
1:750, p<0.01; BCG 1:100, p <0.001). Specifically, after
stimulation with the low BCG concentration, newborn Mos
demonstrated higher log-fold increases for the vast majority of
cytokine/chemokine concentrations as compared to RPMI than
adult Mos (Figure 3A). Cytokines that were significantly
elevated in newborn Mos compared to RPMI included IL-1b,
TNF, IL-12p70, IL-6 and IL-10 (Supplementary Figure 2).
In contrast to neonatal Mos, adult Mos demonstrated higher
log-fold increases for the vast majority of cytokine/chemokines
as compared to RPMI than newborn Mos after stimulation with
the high BCG concentration (Figure 3B). Cytokines that were
significantly elevated compared to RPMI in adult Mos included
TNF, IFNg, IFNa2 and IL-4. Several chemoattractants were also
significantly elevated in the adult Mos only, such as CXCL1,
CCL11 (formerly eotaxin-1), CCL3 and CCL4. At the high BCG
dose, the age-differential effect of BCG was particularly evident
for IL-12p40 and CXCL10 with the same or opposite
directionality of production in newborns and adults, respectively.
To assess the effects of BCG on Mo innate immune memory,
control (RPMI)- or BCG- stimulated human Mos underwent a
procedure to filter out BCG at 24h post-stimulation (as described
in the Methods section) and were then cultured in parallel for
FIGURE 1 | A human in vitro platform to assess age-dependent BCG training. Peripheral venous blood was drawn from healthy adult volunteers and cord blood was
collected from healthy term (≥ 37 weeks gestation) elective cesarean deliveries. After PBMC and CBMC isolation, pure CD33+ Mos were isolated by immunomagnetic
separation and plated in two separate 96-well plates. After 1h of resting, Mos were stimulated with control RPMI medium or with BCG. Supernatants were harvested from
the first plate at 24h post-stimulation for Day 1 cytokine and lactate measurements. The second plate was further cultured after BCG was filtered out at 24h to allow time
for immune training. After intermediate washing and culture medium replenishment steps, trained and untrained (control) monocytes were stimulated at Day 6 with LPS for
24h at which point supernatants were harvested for cytokine and lactate measurements. PBMC, peripheral blood mononuclear cells; CBMC, cord blood mononuclear
cells; Mo, monocyte; sups, supernatants.
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5 more days to allow for in vitro BCG training. At Day 6 of
culture, control and BCG-trained Mos were stimulated with
RPMI (to allow for background correction of TNF
concentrations at Day 6 of culture) or a heterologous stimulus,
LPS, and resulting TNF production was measured 24h later at
Day 7 of culture. Compared to the control RPMI-trained adult
Mos, BCG-trained adult Mos demonstrated enhancement of
subsequent LPS-induced TNF production for 2 of the 3 BCG
concentrations tested (Figure 4). Remarkably, in contrast, BCG-
trained newborn Mos demonstrated a dose dependent decrease
in LPS-induced TNF production compared to the RPMI-trained
(control) newborn Mos for all BCG concentrations tested.
FIGURE 2 | Human newborn monocytes demonstrate distinct BCG-induced primary TNF responses. Human newborn and adult CD33+ monocytes were cultured
in vitro as described in Figure 1. In contrast to adult monocytes, neonatal monocytes demonstrated relatively greater primary TNF responses to BCG. Results are
shown as log10 cytokine concentrations due to skewed distribution of values. N = 7 newborns, 9 adults. D, Day; v/v, volumetric concentrations. Bars indicate mean +
SD. Repeated-measures 1-way ANOVA was used for comparisons across BCG concentrations and 2-way ANOVA was used for comparisons between age groups.
*p < 0.05; ***p < 0.001.
A B
FIGURE 3 | Human newborn and adult monocytes demonstrate distinct primary BCG-induced cytokine and chemokine production at Day 1 of culture. Human
newborn and adult CD33+ monocytes were cultured in vitro as described in Figure 1 then stimulated for 24 hours with (A) low (1:750 vol/vol) or (B) high (1:100 vol/
vol) concentrations of BCG prior to measurement of cytokine and chemokine production in supernatants using a multiplex assay as described in Methods. Data was
normalized to RPMI control, log2 transformed, and represents log2 fold-change. N = 5 newborns and 7 adults; *p < 0.05; **p < 0.01; ***p < 0.001 (blue stars: NB vs.
vehicle; red stars: AD vs. vehicle; black stars: NB vs. AD). Vehicle-(re)stimulated conditions shown in gray.
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The effect of BCG-training on TNF responses was significantly
different for 2 of the 3 BCG concentrations tested (BCG 1:750
and BCG 1:100 v/v) in newborn vs. adult Mos and had the
opposite direction between age groups (Figure 4). Decrease in
TNF concentration at the highest BCG concentration (BCG 1:10 v/
v) was accompanied by a relative loss of Mo viability, which was of
similar magnitude in both age groups (Supplementary Figure 3).
Limited immunophenotyping assessment of Mo cell surface
markers CD14, CD11b and TLR4 by flow cytometry raised the
possibility of distinct BCG-induced phenotypic changes between
newborn and adult Mos (data not shown), but further study of this
phenomenon will be required given the limited nature of this data
set. Notably, vaccination of adult study participants with BCG in
vivo was associated with a decrease in Mo TLR4 expression 2 weeks
post-immunization (17), suggesting early immunophenotypic
changes in trained immunity.
In addition to the aforementioned differences in TNF
production between newborns and adults the impact of BCG
training on a variety of cytokine responses also differed markedly
by age (Figure 5 and Supplementary Table 2). Effects were
significantly different between newborns and adults after
priming with the high BCG dose and restimulation with LPS
[BCG 1:100; RM-ANOVA, p=0.01]; Figure 5B). IL-10
concentrations were not only significantly different, but also
divergent between newborns and adults with a recorded 5 log2-
fold decrease in newborn IL-10 concentrations relative to RPMI
control. The directionality of change in newborns was opposite
from that in adults and statistically significant for CCL5.
Production of IL-12p40, which was significantly upregulated
by primary BCG stimulation, was significantly attenuated by
LPS restimulation of BCG pre-exposed newborn Mos.
We next assessed whether BCG-induced Mo primary
cytokine/chemokine responses on Day 1 correlated with
subsequent trained LPS-induced TNF responses at Day 7.
BCG-induced adult Mo production of IL-1RA on Day 1
inversely correlated with subsequent LPS-induced TNF on Day
7 (R=-0.56, *p=0.04), while newborn Mos demonstrated a
positive correlation for this cytokine (R +0.25) (Figure 6).
Using the signed rank test, correlation coefficients of Day 1
cytokines/chemokines and subsequent Day 7 LPS-induced TNF
production were generally negative in both age groups (p<0.001
for both age groups; Supplementary Figure 4).
As newborns have distinct immunobiology, immunity, and
metabolism (26, 27), as well as BCG-induced primary and
trained cytokine production, we hypothesized that BCG
priming may have distinct immunometabolic effects towards
newborn vs adult Mos. To test this hypothesis, we measured
lactate production in supernatants from our Mo training assay.
BCG-trained adult Mos subsequently treated with LPS produced
2 to 3 log2-fold more lactate compared to RPMI control (Figure
7), as expected given that glycolysis is associated with innate
immune activation in adults (28). In marked contrast to their
adult counterparts, newborn Mos did not exhibit any significant
increase in lactate from baseline but rather trended towards
diminished lactate concentrations, suggesting absence of a
metabolic switch toward increased glycolysis (Figure 7).
DISCUSSION
While there is growing evidence that BCG re-shapes innate
immune responses to tuberculosis-unrelated pathogens
FIGURE 4 | BCG-training induces enhanced LPS-induced TNF responses in adult monocytes but diminished TNF responses in newborn monocytes. Human
newborn and adult CD33+ monocytes were trained with BCG as described in Figure 1. At Day 7 of culture, monocytes were stimulated by LPS prior to collection of
supernatants for TNF ELISA. Relative TNF is the calculated ratio of trained vs. untrained TNF concentrations. N = 7 newborns, 9 adults. D, Day; v/v, volumetric
concentrations. Bars indicate mean + SD. Repeated-measures 1-way ANOVA was used for comparisons across BCG concentrations and 2-way ANOVA was used
for comparisons between age groups. *p < 0.05; **p < 0.01.
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potentially accounting for pathogen- agnostic protection and
clinical benefit, the underlying mechanisms for these
heterologous effects in early life are incompletely characterized
(29). Herein, we demonstrate for the first time that BCG has
distinct age-specific effects on human newborn Mos, including
distinct primary innate cytokine responses as well as
trained immunity.
To characterize age-specific effects of BCG, we utilized a
human in vitro trained immunity platform using primary
human Mos cultured in autologous serum to compare
newborn and adult Mo primary and trained responses to BCG.
We view the use of autologous plasma or serum (intact, i.e. not
heat-treated and from the same individual), repleted with age-
specific immune factors such as maternal antibodies, adenosine
and prostaglandins (30), as an important element of our design
which strives to remain faithful to physiologic conditions that are
relevant in vivo.
Compared to their adult counterparts, human newborn Mos
responded to BCG in a fundamentally distinct manner. With
respect to the primary response to BCG, newborns responded
more robustly to the low concentration (1:750 vol/vol) relative to
RPMI, as demonstrated by significantly enhanced production of
Th1 (IL-12p70 and TNF), Th2 (IL-6 and IL-10) and Th17-
(IL-1ß and GM-CSF) polarizing cytokines, as well as of the
chemoattractant CXCL1. A possible explanation for the
enhanced response of newborn Mos to low-dose BCG
compared to adult Mos could be age-dependent differences in
the magnitude of TLR responses (31–33), bearing in mind that
BCG activates TLR8 (34) that is a power activating pathway in
the newborn (35). The complex nature of BCG as a live
mycobacterial stimulus that activates multiple PRRs (36) likely
explains primary production of broadly acting cytokines.
IL-12p70 induces cytotoxic T cell responses as well as high and
broad humoral immune responses (37). TNF concentrations in
vitro have been used as a benchmark cytokine for BCG-trained
immunity in adults (17), while IL-1b production is implicated in
BCG-trained innate immunity in adults and low birth weight
infants (4, 38). GM-CSF may contribute to the host response
against mycobacterial infection by favoring macrophage M1
polarization after Mycobacterium bovis BCG infection (39), as
well as regulating the neutrophil-mediated inflammatory
response, which mediates BCG-induced protection in a mouse
model of neonatal polymicrobial sepsis (8).
Adults overall responded more robustly to the higher
concentration of BCG (1:100 vol/vol), and specifically exceeded
neonatal responses in production of IL-12p40 and CXCL10
(formerly IP10). In addition to its chemotactic properties,
CXCL10 is also involved in the stimulation of natural killer
and T-cell migration in response to Mycobacterium tuberculosis
infection (40). Selective induction of the IL-12p40 component of
the IL-12 cytokine and subsequent development of T-follicular
helper cells in the lymph node via upregulated IL-12-receptor
signaling is a unique feature of live vaccines. Such BCG-induced
IL-12 pathway activation is mediated via sensing of viability by
TLR8 whose functional alleles correlate with protection vs.
pulmonary TB in BCG-immunized adults, and is not observed
with killed vaccines (34).
With respect to BCG-trained Mo responses to subsequent
stimulation with LPS, neonatal Mos demonstrated a distinct
profile. The directionality and magnitude of cytokine production
of BCG-primed/LPS-restimulated newborn Mos was BCG-
concentration dependent. Specifically, unlike BCG-trained
A B
FIGURE 5 | Distinct LPS-induced cytokine production by BCG-trained human newborn vs. adult monocytes at Day 7 of culture. Human newborn and adult CD33+
monocytes were cultured in vitro as described in Figure 1. Cytokines and chemokines were measured by Multiplex assay. Data shown for BCG concentrations
(A) 1:750 vol/vol and (B) 1:100 vol/vol. Data was normalized to RPMI control, log2 transformed, and represents log2 fold-change. N = 5 newborns and 7 adults;
*p < 0.05; **p < 0.01 (blue stars: NB vs. vehicle; red stars: AD vs. vehicle; black stars: NB vs. AD). Vehicle-(re)stimulated conditions shown in gray.
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adult Mos that demonstrated enhanced LPS-induced cytokine
and chemokine production, BCG-trained newborn Mos
displayed decreased LPS-induced TNF production. Multiplex
analysis revealed that at the low concentration (1:750 vol/vol),
BCG-trained adult Mos demonstrated greater LPS-induced IL-
10 production. In contrast, at the high BCG concentration (1:100
vol/vol), BCG-trained newborn Mos demonstrated diminished
LPS-induced IL-10 and CCL5 production compared to adult
Mos, and significantly decreased IL-12p40 production compared
to RPMI control-treated Mos. A similar tolerogenic response has
been previously reported in whole blood of BCG-vaccinated
infants, who demonstrated increased production of IFN-g in
response to mycobacterial stimulation, but decreased production
of IFN-g in response to subsequent heterologous stimulation and
TLR agonists, as compared to BCG-naïve infants (41).
Correlations between BCG-induced human Mo production of
individual cytokines/chemokines on Day 1 and subsequent LPS-
induced TNF production on Day 7, could serve as novel cytokine/
chemokine biomarker signatures of BCG-induced training in
adults and tolerance in newborns. We found a significant
moderate negative correlation in adults between primary IL-
1RA and trained TNF production, while this correlation was
positive in newborns. As IL-1b has an established role in trained
immunity in adults (38), and IL-1RA may prevent IL-1b binding
to its receptor, the interplay between these two cytokines in
trained immunity and in particular their role in neonatal
trained immunity is worthy of further exploration. In neonates,
BCG vaccine induces production of IL-12, the primary cytokine
that drives CD4+ T cell Th1 differentiation, in a TLR2-dependent
manner (42). Our results indicate that early interaction of BCG
with Mos shapes their subsequent responses to LPS, a
heterologous innate stimulus and raises the possibility that the
cytokines induced early may engage counter-regulatory pathways.
Overall, to the extent that our in vitro results are relevant in vivo,
our observations suggest that BCG-induced trained immunity in the
neonate may attenuate an overwhelming inflammatory response to
potentially noxious subsequent stimuli. With respect to TNF
production, after the initial phase of primary innate immune
FIGURE 6 | Primary BCG-induced cytokine/chemokine concentrations (Day 1, D1) of human monocytes inversely correlate with their trained TNF cytokine
concentrations (Day 7, D7) in newborns and adults. A Forest plot depicts pairwise comparisons between newborn and adult D1 cytokine/chemokine vs. D7 TNF
correlations. Correlations between the cytokine and chemokine data depicted in Figures 3, 5 were quantified using Pearson’s coefficient. Error bars represent the
associated 95% CI.
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activation resulting in increased production and enhanced
chemotaxis, BCG appears to re-wire neonatal Mos for a
tolerogenic response to subsequent stimulation, as occurs in
bacterial sepsis. However, the immune system likely seeks
homeostasis and one way to prevent immunoparalysis, the
extreme version of immune tolerance, is through concomitant
decreased production of anti-inflammatory cytokines such as IL-
10 and IL-12p40. Concurrently, decreased chemotaxis and
angiogenesis may prevent untoward inflammatory sequelae. The
overall pattern of BCG-trained Mo cytokine and chemokine
responses suggests that neonatal Mo responses may serve a
different purpose compared to adult Mo responses, where training
seems to cause Th1 polarization of the innate immune response and
enhancement of the inflammatory response.
A prior in vitro study comparing human cord blood Mos and
adult peripheral blood Mos suggested similar cytokine
production after BCG priming and LPS restimulation (43).
Multiple differences in study design between our study and the
prior one could account for our distinct findings, including a
different study population (US-based cohort in our study vs.
Norwegian in the prior study), use of different BCG formulations
(BCG-Denmark in our study vs. BCG-Bulgaria in the prior),
blood collection from BCG-naïve adult study participants in our
study vs. previously BCG-immunized in the prior, the use of
heparin vs. citrate (a calcium chelator) for blood collection, the
use of untreated autologous newborn vs. adult serum in our
study vs. 10% pooled sterile serum from humans of undescribed
age in the prior study, which could obscure soluble plasma-based
ontogenic differences that shape immune responses (30), and the
method for Mo isolation (isolation of Mos by gradient-
centrifugation in our study vs. adherence, which is an
activating step, in the prior study). Different licensed BCG
formulations vary substantially in their immune-stimulating
capacity, including in induction of IL-1b, a cytokine key to
trained immunity (38), correlating with differences in viability
(44). This is especially notable in light of growing literature
regarding differences between BCG vaccine formulations/strains
in effectiveness in preventing tuberculosis and unrelated
infections (45), with BCG-Denmark being the most frequently
studied formulation for its trained immunity inducing properties
in vivo and in vitro (29). Overall these multiple differences in
study design, could have contributed to the prior study not
demonstrating differences in cytokine production between
newborns and adults.
Upon training with BCG and subsequent stimulation with LPS,
whereas adult Mos demonstrated robust ~2 to 3 log2-fold higher
lactate production compared to RPMI, newbornMos demonstrated
little lactate production, almost comparable to vehicle control
(RPMI). Similar age-dependent immunometabolic differences
were recently observed in another study of activated human cord
blood and adult macrophages (46). Of note, mean lactate
production of neonatal Mos at baseline is slightly lower than that
of adult Mos and directly correlated with pyruvate kinase activity,
which is diminished in newborn vs. adult Mos but reaches adult
levels halfway through infancy (47). Overall, these observations
collectively suggest that glycolytic metabolism of newborn Mos
differs from that of adult Mos, possibly contributing to the distinct
age-specific BCG-induced Mo training. Global metabolomic
FIGURE 7 | Diminished lactate production in human newborn vs. adult monocytes. Human newborn and adult CD33+ monocytes were cultured in vitro as
described in Figure 1. Lactate was measured in culture supernatants post-primary BCG stimulation (Day 1) and post-secondary LPS stimulation (Day 7) using a
colorimetric assay as described in Methods. Lactate production was normalized to the vehicle condition on Day 1 and log2-transformed. N = 4 newborns and 4
adults. Bars indicate mean + SD. *p ≤ 0.05, **p ≤ 0.01 (black star: log2-fold change compared to untrained control RPMI+LPS at Day 7; red stars: NB vs. AD for the
respective conditions).
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profiling of human newborn Mos may provide immunometabolic
signals unique to BCG-trained immunity (48).
To the extent our in vitro results reflect the effects of BCG in
vivo, the protective effects of BCGmay in part rely on attenuating
inflammatory responses to microbial products that signal via
PRRs. The induction of training or tolerance appears to be
dependent on the type and quantity of the microbial stimulus
and host factors. BCG is a live and complex microbial stimulus
that activates multiple PRRs, including TLRs (49–51), C-type
lectin receptors (CLRs) (52), and NOD-like receptors (NLRs)
(17). BCG training of adult Mos was associated with NOD-2-
dependent epigenetic reprogramming (17). Among the PRRs,
TLRs appear to play a prominent role in neonatal responses to
immunization/infection as suggested by: a) an association between
TLR polymorphisms and altered responses to neonatal BCG
immunization (53), and b) selective predisposition to bacterial
infection in young but not older children with genetic defects
affecting TLR downstream signaling (IRAK-4, MyD88) (54). Of
note, a microbial stimulus can elicit different responses
when engaging different receptors. For example, LPS induces
immunosuppressive effects when engaging TLRs vs.
immunopotentiating effects when engaging NLRs (55). Innate
immune memory responses are complex and depend on the age
of the exposed, timingof exposure andpropertiesof the stimulus.Of
note, while neonatalMos express similar quantities of TLRs as their
adult counterparts (55, 56) the downstream consequences of TLR
activation are distinct with age (8). Whether the BCG-induced
tolerance to LPS in neonatalMos observed in our study is related to
TLR-mediated epigenetic reprogrammingwill be an important area
of future investigation.
Our study features multiple strengths, including (a) use of
species (human)- and age (newborn)-specific Mos cultured in
autologous serum, (b) Mo-selection through CD33 instead of
CD14 to avoid activation, (c) study of a licensed WHO-
prequalified BCG formulation/strain, (d) assessment of BCG
concentration-dependent effects, (e) study of both primary (24-
hour stimulation) and trained (LPS-induced cytokine production
at Day 7) immune effects, and (f) measurement of metabolic
activation in the form of lactate production.
As with any research, our study also has some limitations
including (a) an in vitro approach that likely does not capture all of
the immunologic effects of BCG in vivo (17), (b) an exclusive focus
on myeloid CD33+ mononuclear cells which, although important
to BCG responses in vitro and in vivo (51), will not capture the full
range of relevant human leukocyte responses to this live vaccine,
and (c) a focus on LPS as a secondary stimulus which may not
reflect responses to other PRR agonists. Spontaneous in vitro
differentiation of Mos over time towards macrophage phenotypes
is possible and has been previously described in culture medium
supplemented with autologous serum (57). Detailed
immunophenotyping assessment of BCG-treated human
newborn and adult Mos should be pursued in future studies to
provide a fuller picture of BCG’s age-dependent effects. Given the
marked variability between BCG formulations/strains (44), future
studies should also directly compare and characterize the impact
of a range of BCG formulations/strains on the subsequent
responses of a range of human leukocytes and innate stimuli.
In summary, BCG-induced training of human Mos is age-
dependent, suggesting that immune ontogeny may shape
primary and trained innate cytokine responses to BCG. Much
remains to be learned about alterations in neonatal immune
function following infection/vaccination during this critical
period of immune system adaptation and development. Using
BCG as a model to characterize distinct trained immunity in
newborns may inform discovery and development of novel
adjuvants, vaccines and immunotherapies for this vulnerable
population (56).
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